Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomised, controlled trial

Lancet

Volumn 354, Issue 9189, 1999, Pages 1493-1498

  Mann, Michael J ^a   Whittemore, Anthony D ^a   Donaldson, Magruder C ^a   Belkin, Michael ^a   Conte, Michael S ^a   Polak, Joseph F ^a   Orav, E John ^a   Ehsan, Afshin ^a   Dell'Acqua, Giorgio ^a   Dzau, Victor J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLINE; MESSENGER RNA; MYC PROTEIN; OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR E2F;

ADULT; AGED; ARTICLE; BLOOD VESSEL SHUNT; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; DNA SYNTHESIS INHIBITION; FEMALE; FOLLOW UP; GENE THERAPY; GENETIC TRANSFECTION; GRAFT OCCLUSION; GRAFT REJECTION; HUMAN; INGUINAL REGION; INTRAOPERATIVE PERIOD; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATOR GENE; REOPERATION; SAFETY; STENOSIS; TARGET CELL; VEIN GRAFT;

EID: 0033619428     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)09405-2     Document Type: Article

References (31)

1. Campeau L.M., Enjalbert J., Lesperance M.C.et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: a study 10 years after aortocoronary bypass surgery. N Engl J Med. 311:1984;1329-1334.
2. Grondin C.M., Campeau L., Thornton J.C.et al. Coronary artery bypass grafting with saphenous vein. Circulation. 79:1989;24-29.
3. Brewster D.C., LaSalle A.J., Robinson J.G., Strayhorn E.C., Darling C.R. Factors affecting patency of femoropopliteal bypass grafts. Surg Gynecol Obstet. 157:1983;437-442.
4. Reardon M.J., Conklin L.D., Reardon P.R., Baldwin J.C. Coronary artery bypass conduits: review of current status. J Cardiovasc Surg. 38:1997;201-209.
5. Motwani J.G., Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 97:1998;916-931.
6. Cox J.L., Chaisson D.A., Gotleib A.I. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis. Prog Cardiovasc Dis. 34:1991;45-68.
7. Zwolak R.M., Adams M.C., Clowes A.W. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg. 5:1987;126-136.
8. Tanaka H., Sukhova G.K., Swanson S.J.et al. Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury. Circulation. 88:1993;1788-1803.
9. Landry D.B., Couper L.L., Bryant S.R., Lindner V. Activation of the NF-kappa B and I kappa B system in smooth muscle cells after rat arterial injury: induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol. 151:1997;1085-1095.
10. Loppnow H., Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 85:1990;731-738.
11. Park T.C., Harker C.T., Edwards J.M.et al. Human saphenous vein grafts explanted from the arterial circulation demonstrate altered smooth-muscle and endothelial responses. J Vasc Surg. 18:1993;61-69.
12. Cross K.S., El-Sanadiki M.N., Murray J.J.et al. Functional abnormalities of experimental autologous vein graft neoendothelium. Ann Surg. 208:1988;631-638.
13. O'Neil G.S., Chester A.H., Schyns C.J.et al. Effect of surgical preparation and arterialization on vasomotion of human saphenous vein. J Thorac Cardiovasc Surg. 107:1994;699-706.
14. Mann M.J., Gibbons G.H., Kernoff R.S.et al. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA. 92:1995;4502-4506.
15. Mann M.J., Gibbons G.H., Tsao P.S.et al. Cell cycle inhibition preserves endothelial function in genetically engineered vein grafts. J Clin Invest. 99:1997;1295-1301.
16. Morishita R., Gibbons G.H., Ellison K.E.et al. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 93:1994;1458-1464.
17. Morishita R., Gibbons G.H., Ellison K.E.et al. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 90:1993;8474-8478.
18. Morishita R., Gibbons G.H., Kaneda Y., Ogihara T., Dzau V.J. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene. 149:1994;13-19.
19. DeGregori J., Kowalik T., Nevins J.R. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol. 15:1995;4215-4224.
20. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
21. Mann M.J., Kernoff R., Dzau V.J. Intra-operative transfection with E2F decoy oligonucleotide yields long term resistance to vein graft atherosclerosis. J Invest Med. 45:1997;224. (abstr).
22. Mann M.J., Gibbons G.H., Hutchinson H.et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci USA. 96:1999;6411-6416.
23. Lundell A., Lindblad B., Bergqvist D., Hansen F. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study. J Vasc Surg. 21:1995;26-33.
24. Idu M.M., Blankenstein J.D., de Grier P.et al. Impact of a color-flow duplex surveillance program on infrainguinal vein graft patency: a five year experience. J Vasc Surg. 17:1993;42-53.
25. Bergamini T.M., George S.M., Massey H.T.et al. Intensive surveillance of femoropopliteal-tibial autogenous vein bypasses improves long term graft patency and limb salvage. Ann Surg. 221:1995;507-516.
26. Rutherford R.B., Flanigan D.P., Gupta S.K. Suggested standards for reports dealing with lower extremity ischemia. J Vasc Surg. 4:1986;80-84.
27. Rutherford R.B. J Vasc Surg. 7:1988;718.
28. Haywood G.A., Gullestad L., Katsuya T.et al. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation. 95:1997;1201-1206.
29. Braun-Dullaeus R.C., Mann M.J., Dzau V.J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 98:1998;82-89.
30. Heagerty A.M. Changes in vascular morphology in essential hypertension. J Hum Hypertens. 5:1991;3-8. (suppl 1).
31. Koffi I., Safar M.E., Labat C., Lacolley P., Benetos A., Mourad J.J. Arterial structural changes with verapamil in spontaneously hypertensive rats. Am J Hypertens. 12:1999;732-738.